Monoallelic expression determines oncogenic progression and outcome in benign and malignant brain tumors

Cancer Research

Volumn 72, Issue 3, 2012, Pages 636-644

  Walker, Erin J ^a   Zhang, Cindy ^a   Castelo Branco, Pedro ^a   Hawkins, Cynthia ^a   Wilson, Wes ^a   Zhukova, Nataliya ^a   Alon, Noa ^a   Novokmet, Ana ^a   Baskin, Berivan ^a   Ray, Peter ^a   Knobbe, Christiane ^b   Dirks, Peter ^a   Taylor, Michael D ^a   Croul, Sidney ^a,b   Malkin, David ^a   Tabori, Uri ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; RNA;

ADAMTS5 GENE; ADVANCED CANCER; ALDH1A2 GENE; ARTICLE; BENIGN TUMOR; BRAIN BIOPSY; BRAIN TUMOR; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CHOROID PLEXUS TUMOR; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; GENE; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; GLIOMA; HUMAN; HUMAN TISSUE; IYD GENE; MALIGNANT NEOPLASTIC DISEASE; MONOALLELIC EXPRESSION; MUC16 GENE; NTRK3 GENE; NUCLEIC ACID ANALYSIS; ONCOGENE; ONCOGENE HTERT; ONCOGENE IDH1; ONCOGENE TP53; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SLC38A1 GENE; ST13 GENE; TIMELESS GENE; TULP4 GENE; TUMOR GROWTH;

ADULT; ALLELES; AUTOPSY; BRAIN NEOPLASMS; CELL LINE; CELL LINE, TUMOR; CHILD; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; ISOCITRATE DEHYDROGENASE; LOSS OF HETEROZYGOSITY; MUTATION; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; SURVIVAL ANALYSIS; TELOMERASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84863082525     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2266     Document Type: Article

References (28)

1. Chess A, Simon I, Cedar H, Axel R. Allelic inactivation regulates olfactory receptor gene expression. Cell 1994;78:823-34. (Pubitemid 24294457)
2. Goldmit M, Bergman Y. Monoallelic gene expression: a repertoire of recurrent themes. Immunol Rev 2004;200:197-214. (Pubitemid 38998203)
3. Gimelbrant A, Hutchinson JN, Thompson BR, Chess A. Widespread monoallelic expression on human autosomes. Science 2007;318:1136-40. (Pubitemid 350134896)
4. Frost JM, Monk D, Stojilkovic-Mikic T, Woodfine K, Chitty LS, Murrell A, et al. Evaluation of allelic expression of imprinted genes in adult human blood. PLoS One 2010;5:e13556.
5. Wang J, Valo Z, Smith D, Singer-Sam J. Monoallelic expression of multiple genes in the CNS. PLoS One 2007;2:e1293.
6. Voutsinas GE, Stavrou EF, Karousos G, Dasoula A, Papachatzopoulou A, Syrrou M, et al. Allelic imbalance of expression and epigenetic regulation within the alpha-synuclein wild-type and p.Ala53Thr alleles in Parkinson disease. Hum Mutat 2010;31:685-91.
7. Pinheiro H, Bordeira-Carriço R, Seixas S, Carvalho J, Senz J, Oliveira P, et al. Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer. Hum Mol Genet 2010;19:943-52.
8. Tan AC, Fan JB, Karikari C, Bibikova M, Garcia EW, Zhou L, et al. Allele-specific expression in the germline of patients with familial pancreatic cancer: an unbiased approach to cancer gene discovery. Cancer Biol Ther 2008;7:135-44.
9. Milani L, Lundmark A, Nordlund J, Kiialainen A, Flaegstad T, Jonmundsson G, et al. Allele-specific gene expression patterns in primary leukemic cells reveal regulation of gene expression by CpG site methylation. Genome Res 2009;19:1-11.
10. Pastinen T, Sladek R, Gurd S, Sammak A, Ge B, Lepage P, et al. A survey of genetic and epigenetic variation affecting human gene expression. Physiol Genomics 2004;16:184-93. (Pubitemid 38420035)
11. Porter KR, McCarthy BJ, Freels S, Kim Y, Davis FG. Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro Oncol 2010;12:520-7.
12. Dubuc AM, Northcott PA, Mack S, Witt H, Pfister S, Taylor MD. The genetics of pediatric brain tumors. Curr Neurol Neurosci Rep 2010;10:215-23.
13. Nikiforova MN, Hamilton RL. Molecular diagnostics of gliomas. Arch Pathol Lab Med 2011;135:558-68.
14. Sievert AJ, JacksonEM, Gai X, Hakonarson H, Judkins AR, Resnick AC, et al. Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol 2009;19:449-58.
15. Qu HQ, Jacob K, Fatet S, Ge B, Barnett D, Delattre O, et al. Genome-wide profiling using single-nucleotide polymorphism arrays identifies novel chromosomal imbalances in pediatric glioblastomas. Neuro Oncol 2010;12:153-63.
16. Lim DHK, Maher ER. Genomic imprinting syndromes and cancer. In: Zdenko H, Toshikazu U, editors. Advances in genetics: Academic Press; 2010. p. 145-75.
17. Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, Russell R, et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 2009;4:568-80.
18. Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, Malmer B, et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet 2009;41:899-904.
19. Wrensch M, Jenkins RB, Chang JS, Yeh RF, Xiao Y, Decker PA, et al. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet 2009;41:905-8.
20. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
21. Tabori U, Shlien A, Baskin B, Levitt S, Ray P, Alon N, et al. TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors. J Clin Oncol 2010;28:1995-2001.
22. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathologica 2008;116:597-602.
23. Kloosterhof NK, Bralten LB, Dubbink HJ, French PJ, van den Bent MJ. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? Lancet Oncol 2011;12:83-91.
24. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765-73.
25. Fearon ER, Vogelstein B.A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
26. Lambertz I, Nittner D, Mestdagh P, Denecker G, Vandesompele J, Dyer MA, et al. Monoallelic but not biallelic loss of Dicer1 promotes tumorigenesis in vivo. Cell Death Differ 2010;17:633-41.
27. Huse JT, Brennan C, Hambardzumyan D, Wee B, Pena J, Rouhanifard SH, et al. The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev 2009;23:1327-37.
28. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathologica 2010;120:707-18.